StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

NASDAQ TCON opened at $0.03 on Thursday. TRACON Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $14.75. The company has a fifty day moving average of $0.08 and a 200-day moving average of $0.53. The company has a market capitalization of $107,756.00, a P/E ratio of 0.01 and a beta of 1.43.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.